Production (Stage)
BioRestorative Therapies, Inc.
BRTX
$1.66
$0.063.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -42.26% | -81.46% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -42.26% | -81.46% | |||
| Cost of Revenue | -12.12% | -81.87% | |||
| Gross Profit | -44.75% | -81.43% | |||
| SG&A Expenses | 190.63% | -9.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 76.79% | 8.44% | |||
| Operating Income | -78.71% | -17.63% | |||
| Income Before Tax | -226.37% | -49.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -226.37% | -49.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -226.37% | -49.91% | |||
| EBIT | -78.71% | -17.63% | |||
| EBITDA | -80.16% | -17.92% | |||
| EPS Basic | -217.28% | -49.85% | |||
| Normalized Basic EPS | -6,984.48% | 106.90% | |||
| EPS Diluted | -216.34% | -50.30% | |||
| Normalized Diluted EPS | -6,984.48% | 106.90% | |||
| Average Basic Shares Outstanding | 2.85% | 0.05% | |||
| Average Diluted Shares Outstanding | 2.85% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||